Company profile

Actio Biosciences, Inc.

Privately held: no public share price (San Diego-based, venture-backed private biotech developing ABS-1230 (KCNT1 inhibitor) for KCNT1-related epilepsy; closed a $66M Series B in June 2025 led by Regeneron Ventures and Deerfield Management. No public listing. Sources: https://clinicaltrials.gov/study/NCT07156201 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://www.businesswire.com/news/home/20250618424417/en/Actio-Biosciences-Secures-$66-Million-Series-B-Financing-to-Advance-Genetics-Driven-Pipeline-of-Small-Molecule-Therapeutics-for-Rare-and-Common-Diseases Entity resolved by asset-pipeline-v2.)

Assets

(1 total)

1Total Assets

0Approved

0Phase 3 / Filed

1Phase 1–2 / Early

1Diseases

Showing 1 of 1 assets

		Target & Modality
ABS-1230	Phase 2	KCNT1 (KNa1.1/Slack) channelSmall molecule	Epilepsy

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.